CANTA — Cantargia AB Share News
0.000.00%
Last trade - 00:00- SEK533.52m
- SEK275.49m
- SEK316.70m
Brief: Cantargia And GEICAM Present Nadunolimab Updated Phase 1 Clinical Data
Brief: Cantargia Expands Can10 Phase 1 Clinical Program Building On Positive Results
Brief: Cantargia 9M EBIT SEK -127.9 Million
Brief: Cantargia Announces CAN10 Results
Brief: Cantargia Reports New Results From Studies Investigating Nadunolimab
Brief: Cantargia Reports Positive Results On Biomarkers, Safety In CAN10 Phase 1 Clinical Study
Brief: Cantargia Presents New Results At EADV 2024
Brief: Cantargia Presents Positive Results Of Nadunolimab Combination Therapy
Brief: Cantargia H1 EBIT SEK -85.5 Million
Brief: Cantargia Reports Progress And Strong Biomarker Data From Phase I Clinical Trial With Can10
Brief: Cantargia Presents Phase 2 Clinical Data In Pancreatic Cancer With Nadunolimab
Brief: Cantargia Q1 Operating Loss Narrows To SEK 41.7 Mln
Brief: Cantargia Q1 EBIT SEK -41.7 Million
Brief: Cantargia Says Third Party Withdraws Appeal Related To Cantargia Patent
Brief: Cantargia Publishes New Data On Can10 Antibody
Brief: Cantargia Publishes Preclinical Data On Potential Of CAN10
Brief: Cantargia Publishes Data Highlighting Potential Of CAN10 In Atherosclerosis
Brief: Cantargia Reports Progress Towards Start Of DOD-Sponsored Clinical Trial
Brief: Cantargia Reports New Preclinical Data On Antitumor Effects Of Nadunolimab